18:31 , Nov 30, 2018 |  BC Week In Review  |  Company News

Ascletis adds HBV therapy to portfolio through Roche partnership

With one marketed HCV therapy in China and another under review, Ascletis Pharma Inc. (HKSE:1672) extended its commercial viral hepatitis footprint in the country on Nov. 20 with exclusive rights to marketed HBV drug Pegasys...
22:05 , Nov 20, 2018 |  BC Extra  |  Company News

Ascletis adds marketed HBV drug from Roche to Chinese portfolio

With one marketed HCV therapy in China and another under review, Ascletis Pharma Inc. (HKSE:1672) extended its commercial viral hepatitis footprint in the country on Tuesday with exclusive rights to marketed HBV drug Pegasys peginterferon...
22:27 , Nov 1, 2018 |  BC Extra  |  Politics & Policy

FDA guides development of finite therapies to cure HBV

FDA released draft guidance Thursday to encourage development of finite, curative HBV treatments that have a low risk of virologic relapse and minimal risk of liver disease progression after treatment. FDA recommended developers use a...
17:59 , Oct 12, 2018 |  BC Week In Review  |  Company News

Arbutus falls on HBV program updates

Arbutus Biopharma Corp. (NASDAQ:ABUS) lost $3.09 (34%) to $6 on Oct. 9 after announcing updates for two of its HBV programs. The move translated to a loss of over $170 million in the company's market...
23:50 , Oct 9, 2018 |  BC Extra  |  Clinical News

Arbutus falls on HBV program updates

Arbutus Biopharma Corp. (NASDAQ:ABUS) lost $3.09 (34%) to $6 on Tuesday after announcing updates for two of its HBV programs. The move translated to a loss of over $170 million in the company's market cap....
19:25 , Oct 5, 2018 |  BC Week In Review  |  Company News

Deal adds HBV therapy to Janssen pipeline, validates Arrowhead platform

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) granted Janssen Pharmaceuticals Inc. rights to an HBV candidate for its curative combination toolbox. The deal, worth up to $3.7 billion, is Arrowhead's first billion dollar deal for a platform that...
11:31 , Oct 4, 2018 |  BC Extra  |  Company News

Deal satisfies Janssen HBV strategy, validates Arrowhead platform

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) granted Janssen Pharmaceuticals Inc. rights to an HBV candidate for its curative combination toolbox. The deal, worth up to $3.7 billion, is Arrowhead's first billion dollar deal for a platform that...
22:42 , Sep 21, 2018 |  BioCentury  |  Product Development

Arrowhead refills its quiver

Arrowhead Pharmaceuticals Inc.’s tox blowup in 2016 set back its clinical timelines, but it also prompted the company to bring a more versatile platform online faster than originally planned. Early data from replacement candidates suggest...
15:19 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

Arrowhead's third-generation RNAi shows initial efficacy against HBV

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) reported initial data showing that monthly doses of its third-generation RNAi therapy ARO-HBV reduced circulating hepatitis B surface antigen (HBsAg) levels in a broad population of patients with chronic HBV infection....
20:42 , Sep 6, 2018 |  BC Extra  |  Clinical News

Arrowhead's third-generation RNAi shows initial efficacy against HBV

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) gained $5.29 (38%) to $19.39 Thursday after reporting initial data showing that monthly doses of its third-generation RNAi therapy ARO-HBV reduced circulating HBV surface antigen (HBsAg) in a broad population of...